Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Eli Lilly finds impurity in compounded tirzepatide

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Latest news

Vima banks $100m in Series A to progress Parkinson’s drug

The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

Wegovy portfolio growth shifts to the pill as injectable sales forecast to plateau

While the injectable retains convenience advantages in dosing frequency, the pill addresses needle aversion and may facilitate broader uptake in primary care settings.

WHO directs antibiotic development to priority pathogens

WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.

PsiQuantum and National Cancer Center Japan partner on quantum computing

PsiQuantum will work with the National Cancer Center Japan to develop fault-tolerant algorithms and quantum applications.

PRISM BioLab partners with Receptor.AI for molecule discovery

The collaboration targets disease areas where conventional small molecule drug discovery has faced challenges.